What Happened?
San Francisco, CA-based Vishwanath Lingappa as Chief Technical Officer and CoChief Eexecutive Officer
About the Company
Prosetta Biosciences, Inc. is an 11-year old biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. The incorporation of the CFPSS in our drug discovery platform, has lead to the identification of small molecules which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids (the protein shell that protects the DNA or RNA genome of a virus). Prosetta has successfully produced highly potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against Influenza, HIV and HCV.
About the Person
Vishwanath R. Lingappa is currently Chief Technology Officer and Co-Chief Eexecutive Officer of Prosetta Biosciences, Inc., in San Francisco. In these roles he is responsible for the advancement of Prosettas scientific programs. He received a B.A. degree from Swarthmore College in 1975, his Ph.D. degree from The Rockefeller University in 1979, and M.D. degree from Cornell University Medical College in 1980. Dr. Lingappa completed residency training in Internal Medicine before joining the faculty in the Departments of Physiology and Medicine at the University of California, San Francisco (UCSF) in 1982, where he ran an NIH-funded basic research laboratory for over 20 years. It was during this time that the core discoveries on which Prosettas science is based were made and refined in his laboratory.
Info Source
News
Short Profile